Amgen Hopes Kyprolis Label Expansion Will Give It A Leg Up In The Myeloma Market
Firm believes addition of data from the ENDEAVOR trial, and new claims, will establish the proteasome inhibitor as a backbone of choice across lines of therapy.
Firm believes addition of data from the ENDEAVOR trial, and new claims, will establish the proteasome inhibitor as a backbone of choice across lines of therapy.